CD109 Inhibition for Bone Density Without Broad Hormonal Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteopenia and osteoporosis, including hormonal and mineral supplements, have undesirable side effects and uncertain efficacy in reducing fracture risk, while the role of CD109 in bone mineral density is unclear.
Innovation Solution
Administering CD109 inhibitors, such as antisense nucleic acid molecules or small interfering RNAs, to subjects with specific CD109 missense variant nucleic acid molecules to inhibit CD109 expression, thereby treating or preventing osteopenia and osteoporosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If hormonal compounds are used to treat osteoporosis, then bone density is improved, but cancer risk increases
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (CD109 protein) that mediates bone loss, rather than using broad hormonal compounds. By administering CD109 inhibitors, the treatment selectively blocks the harmful pathway while avoiding the systemic side effects of hormone replacement therapy, thus improving bone density without increasing cancer risk
Solution Approach 2:
The patent introduces CD109 inhibitors as an intermediary substance that blocks the interaction between TGF-β and its receptors in bone cells. This intermediary approach prevents the downstream effects leading to bone loss without requiring direct hormonal replacement, thereby achieving therapeutic benefit while avoiding the harmful intermediary effects of exogenous hormones
2Strength
If synthetic or non-mammalian hormones are used to treat osteoporosis, then bone density is improved, but cardiovascular and neurological disorder risks increase
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (CD109 protein) that mediates bone loss, rather than using broad hormonal compounds. By administering CD109 inhibitors, the treatment selectively blocks the harmful pathway while avoiding the systemic side effects of hormone replacement therapy, thus improving bone density without increasing cardiovascular or neurological disorder risks
Solution Approach 2:
The patent changes the therapeutic parameter from hormonal concentration to CD109 inhibition level. By measuring and targeting CD109 expression and activity rather than hormone levels, the treatment achieves bone protection through a different physiological parameter that does not carry the same cardiovascular and neurological risks associated with synthetic hormones
3Quantity of substance
If mineral supplements are used to treat osteopenia, then bone mineral replenishment is achieved, but fracture risk reduction remains uncertain
Solution Approach 1:
The patent applies preliminary action by blocking CD109-mediated bone resorption before significant bone loss occurs. By inhibiting the osteoclast activation pathway upstream, the treatment prevents bone mineral depletion rather than merely supplementing minerals after loss has occurred, thereby more reliably preventing fractures
Solution Approach 2:
The patent replaces the passive mineral supplementation approach with an active biological mechanism modulation. Instead of relying on mineral absorption and deposition processes, the treatment actively inhibits the cellular mechanism (CD109-TGF-β signaling) that drives bone resorption, providing more reliable fracture prevention through direct mechanistic intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces the risk and symptoms of osteopenia and osteoporosis by targeting CD109, providing a safer and potentially more effective treatment option with reduced side effects.
Implementation Method 1
Administering CD109 inhibitors, such as antisense nucleic acid molecules or small interfering RNAs, to subjects with specific CD109 missense variant nucleic acid molecules to inhibit CD109 expression
Implementation Method 2
Administering CD109 inhibitors, such as antisense nucleic acid molecules or small interfering RNAs, to subjects with specific CD109 missense variant nucleic acid molecules to inhibit CD109 expression
Data Source
AI summary
The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.